REPLIMUNE GROUP INC. - COMMON STOCK

Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

03 ноя 2023 19:30:00 Источник Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 сен 2023 16:01:00 Источник Nasdaq GlobeNewswire

Replimune Announces Appointment of Emily Hill as Chief Financial Officer

19 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

03 авг 2023 08:00:01 Источник Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

01 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Replimune Announces Sander Slootweg will Depart from its Board of Directors

20 июл 2023 08:00:01 Источник Nasdaq GlobeNewswire

Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting

06 июн 2023 10:00:00 Источник Nasdaq GlobeNewswire

Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors

05 июн 2023 08:00:00 Источник Nasdaq GlobeNewswire

Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

03 июн 2023 14:15:00 Источник Nasdaq GlobeNewswire

Replimune to Present at the Jefferies Global Healthcare Conference

01 июн 2023 16:01:00 Источник Nasdaq GlobeNewswire

Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

25 май 2023 17:00:00 Источник Nasdaq GlobeNewswire

Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update

18 май 2023 08:00:00 Источник Nasdaq GlobeNewswire

Replimune to Participate in the Piper Sandler Spring Biopharma Symposium

09 май 2023 08:00:01 Источник Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

08 мар 2023 08:00:01 Источник Nasdaq GlobeNewswire

Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update

09 фев 2023 08:00:01 Источник Nasdaq GlobeNewswire

Replimune to Present at the Virtual SVB Securities Global Biopharma Conference

07 фев 2023 08:00:02 Источник Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 янв 2023 08:05:00 Источник Nasdaq GlobeNewswire

Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer

04 янв 2023 08:00:01 Источник Nasdaq GlobeNewswire

Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 янв 2023 08:00:01 Источник Nasdaq GlobeNewswire

Replimune Announces Pricing of Public Offering

08 дек 2022 21:04:34 Источник Nasdaq GlobeNewswire